Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience
← catalyst calendarNCT07777965 · readout ≤ 100 d
Sponsored by Viatris Inc. (industry) · VTRS — their whole pipeline →. With Dr. Vince Clinical Research.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Other
Enrollment
48estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-21
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-18 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Non-dependent, Recreational Sedative Users
Interventions
- Drug: Alprazolam (Xanax)
- Drug: Placebo
- Drug: Gabapentin (Neurontin® (Registered Trademark))
- Drug: Gabapentin (Neurontin® (Registered Trademark))
Primary outcome
what the primary-completion date above is the date OFBipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax)
measured Up to 24 hours after treatments
Permalink · VTRS's whole pipeline · Catalyst calendar · Every registered study · What changed